Method of aseptic whirlbone necrosis and perthers disease treatment |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IPC classes for russian patent Method of aseptic whirlbone necrosis and perthers disease treatment (RU 2357736):
      
Method of prevention of postoperative osteomyelitis / 2343925
For prevention of postoperative osteomyelitis use composition consisting of antimicrobial substances, dissolved in high-molecular polyvinylpyrolidone with molecular mass of 1 million. The composition is administered using a syringe into the medullar channel and in the intermuscular spaces surrounding a bone, on a measure of sealing of soft tissues after operation. Invention allows to give antimicrobial activity to tissues surrounding wound for long time at the expense of slow biodegradation of polyvinylpyrolidone and long-term diffusion of antimicrobial substances from a composition in a tissue.
 Amorphous alendronate monosodium, methods of production, based pharmaceutical composition and method of inhibition of bone resobrtion / 2334751
Invention refers to method of production of amorphous alendronate monosodium and to solid pharmaceutical composition having property to invoke bone bulk expansion and containing therapeutically effective amount of amorphous alendronate monosodium, produced by stated method. Method of production of amorphous alendronate monosodium includes solvent removal from alendronate monosodium solution using spray drying.
 Pharmaceutical formulation applied for prevention and treatment of bone tissue resorption of any etiology, transdermal delivery and treatment technique / 2325165
Given invention refers to pharmaceutical field, specifically to pharmaceutical formulation of gel dosage form applied for prevention and treatment of osteoporosis including as an active component bisphosphonate incorporated in phospholipid vesicles generated from lipid and hydrophilic phases, including components in the following proportions, mass %: bisphosphonate 0.01-2.0; egg lecithin 1.0-6.0; pine essence 0.05-0.2; camphor oil 0.01-1.0; olive oil 0.01-5.0; vitamin E 0.01-0.15; vitamin D 0.01-0.2; vitamin F 0.2-0.4; carbopole 0.4-0.6; NaOH 0.42; glycerol 2.0-4.0; nipagine 0.3; nypazole 0.1; water and others. In addition invention refers to treatment of bone tissue resorption of any etiology and osteoporosis for patients suffering from gastrointestinal disturbance with this composition.
 Osteoprotegrin, its application for preparation of pharmaceutical composition (variants), production of food substance (variants) and fodder, food substance, fodder and pharmaceutical composition for prevention and treatment of disorders related to bone remodeling, and/or immune disorders / 2324705
This invention is related to biotechnology, to be more precise, to preparation of proteins out of milk, and may be used for prevention or treatment disorders related to metabolism in bones and immune function. Osteoprotegrin is prepared out of human or cow milk and has glycolysis profile that produces polypeptide with molecular mass of approximately 80, 130 and 200 kilodaltons. Prepared protein is used in structure of food substance and pharmaceutical composition for prevention or treatment of disorders related with bone remodeling, and/or immune disorders. Also prepared protein is added to make fodder.
 Method for treating and preventing the loss of bony tissue / 2319483
The present innovation deals with treating and preventing the loss of bony tissue and/or increased development of bony tissue. For this purpose it is necessary to apply 15-lipoxygenase inhibitors. These molecules could be introduced either individually or in combination with agents that inhibit the resorption of bony tissue or additional agents that regulate calcium resorption out of bony tissue or increase the accumulation of bony tissue. The innovation enables to widen the assortment of medicinal preparations for treating diseases associated with the loss of bony tissue, such as osteoporosis, osteoarthritis, Paget's disease and those of periodontium and, also, the fractures.
Osteoplastic composite material / 2307661
Material comprises deproteinized allobone granules as filler, the granules being at least 1 mm large, and hydrophylic dimethylacrylate as monomer. Bone cement, filler and monomer are taken in 1:1:0.5 proportion, respectively.
 Analogs of vitamin d / 2301794
Invention relates to novel triaromatic compounds, namely, analogs of vitamin D of the general formula (I):
 Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using / 2299741
Invention relates to drugs used in prophylaxis and treatment of the locomotor system, in particular, degenerative-dystrophic joint and backbone diseases. Invention proposes a pharmaceutical composition normalizing metabolism in osseous and cartilage tissues and comprising the effective amount of peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component, and pharmaceutically acceptable carrier. Invention proposes peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] possessing the biological activity manifesting as normalization of metabolism in osseous and cartilage tissues. Invention proposes a method for prophylaxis and treatment of locomotor system by normalization of metabolism in osseous and cartilage tissues involving administration in a patient of a pharmaceutical composition containing as an active component peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] in the dose 0.01-100 mcg/kg of the body mass for at least once per a day for time necessary for achievement of the therapeutic effect. Invention can be used as agent normalizing metabolism in osseous and cartilage tissues.
 Method for optimizing bone reparative regeneration / 2297217
Method involves preparing bioantioxidant Thiophan solution with alpha-tocopherol oil solution taken as base taken in Thiophan 5 mg and alpha-tocopherol 5 ml proportion. The bioantioxidant solution is introduced at a dose of 3 mg/kg of body weight into intramedullary canal of damaged bone through polyvinylchloride catheter once a day, daily during 4 days, then, every other day. Total treatment course is 10 injections long.
Composition for bone tissue treatment in damages of inflammation etiology / 2296575
Claimed composition contains nutrient medium, 10 % serum of cow embryo, human fibroblast diploid cells and gel filler in the next component ratio (in 1 ml): nutrient medium 0,01-0,9; 10 % serum of cow embryo 0,001-0,2; suspension of human fibroblast diploid cells 1x105- 5x109 cells; and balance: gel filler. As human fibroblast diploid cells composition contains human fibroblast diploid cell strain from embryo lung tissue for substitutive therapy or human fibroblast diploid cell strain from embryo skin-muscle tissue for substitutive therapy. As gel filler 5 % polyethylene oxide may be used.
Method of autoblood treatment before reinfusion / 2342939
Method of autoblood treatment before reinfusion includes separation of the blood taken from the patient, into plasma and packed red cells. A blood sampling at the patient carry out twice on 350-450 ml, in the beginning for 10-15 days, and second time 3-5 days prior to reinfusion, with placing hemocomponents in containers with haemopreservative. The obtained autoplazma is frozen at temperature -36°-42°C. Before reinfusion the autoplasma is heated up to temperature +37°C, passed through a polymeric or organic haemosorbent (type SKN or KAU). The autologous packed red cells before reinfusion are unitary washed in 300 ml of 1% NaCL solution. The method allows raising quality of prepared autoblood components before planned surgical interventions or before coming cytoscopic therapy.
 Method of hepatitis type c treatment / 2336096
Before pharmacotherapy course including Ribavirin and Interferon alpha-2a, 5 cryoplasmasorbtion procedures (CPS) are performed every 2 days. Thereafter these procedures are repeated once a month until pharmacotherapy termination.
Method of treatment for chronic trichomoniasis / 2331427
Susceptibility of pathogenic organism to antiprotozoan drugs is determined. At the preliminary stage sporobacterin, sulodexide, methadoxil, and vobenzyme are injected; the prostate is affected by ultrasound exposure. After that at the etiotropic treatment stage, the blood is taken and separated in plasma, erythrocyte suspension, and leukocyte suspension fractions by sequential centrifuging at 800 rpm and 1800 rpm speed and temperature +4°C. The plasma is eliminated and replaced by crystalloid solution. The erythrocyte suspension is injected intravenously to the patient. The leukocyte suspension, with 0.5 ml ATP added, is affected by semiconductor laser radiation exposure at λ=0.70 mcm, then 0.75 g of metronidazol in solution is added and, after incubation at +37°C, injected to the patient. Simultaneously nifuratel is administered perorally in 200 mg dose twice a day. The procedure is repeated during 8 days. At the rehabilitation therapy stage during 10 days trilact is administered by 2 doses twice a day, as well as polyvitamin mix "Alpha-Vit". The method provides directed metronidazol transport into infection focuses, activates autoblood cells metabolism and phagocytic, adhesive, and migration leukocyte activities, stimulates resorption of fibrotic degenerated chronic inflammation niduses in urino-genital tract, decreases manifestation of side effects.
Method of production of haemoglobin solutions purified of stromal components / 2329826
Invention refers to medicine, rather to transfusiology, specifically to release of haemoglobin solutions purified of stromal components. Method implies that erythrocyte mass is isolated from blood, washed, hemolysed, centrifugated with following supernatant purification from all soluble impurities by anionites, thus supernatant is purified from soluble impurities by addition of anionites as flocculent of particle size 90-160 microns at mass ratio flocculent/haemoglobin = 1.0-4.0, thus pH is maintained at values 6.6-7.2. Invention provides scaled technological process of production of haemoglobin purified of stromal components.
 Leukocyte inactivation module (lim) / 2327490
Substance of invention includes application of ligand associated with carrier, where ligand is protein FasL, or Fas leukocyte receptor-directed antibody, to reduce leukocyte activity for extracorporal application. Besides, this invention provides method of leukocyte activity reduction my means of specified module.
Preventive method of suppurative-septic complications casued by severe combined injury / 2326687
For this purpose at admission stage injury severity is detected. Intensive therapy is carried out. On the third day after injury indicators of systemic inflammatory response syndrome are detected. If leukocyte amount is increased to not more than 20% of norm, stab shift is not more than 15%, tachycardia is not more than 90 per minute, thrombocyte amount is decreased to not more than 50% of original, and C - reactive protein in blood serum is more 3 mg/l, systemic inflammatory response stage is considered as immunosuppression. Then 10% of circulating blood volume is exfused followed with plasmapheresis. Cell mass is added with "Rhoncoleukine" dosed 500000 ME, produced mixture is incubated and introduced in blood.
 Method of peget breast cancer treatment / 2325920
Can be applied for treatment of Peget breast cancer. Method substance implies that autoblood is sampled from peripheral vein in two bottles with hemo-preserving agent, 100 ml in each bottle. First bottle is added with doxorubicin dosed 50 mg/m, and second one is added with 5-fluorouracil dosed 750 mg/m2 , after that both bottles are incubated in thermostat at temperature 37°C during 30 minutes. Content of first bottle is injected with intravenous dropper followed by the second bottle content on the first and the eighth day of treatment course. Additionally from the first to the seventh day of treatment course cyclophosphan dosed 200 mg/m2 is injected intramuscularly. Then in 2 weeks after the last injection of chemical agents surgical procedure is performed in radical volume.
Immunoglobulin removing sorbent / 2325172
Sorbent is offered to remove immunoglobulin from human blood plasma. This sorbent contains agarous matrix covalently combined with ligand. As a ligand at that it contains F(ab)2 fragments of specific affinely-purified polyclonal antibodies blocking human immunoglobulin G. Sorbent is actually biologically inert, biocompatible agarous matrix. Sorbent is characterized with higher sorptive capacity and safety of immunosorbents used practical purposes, specifically for therapeutic aphaeresis in comparison to well-known polyclonal bodies based sorbents.
Method for treating uterine choriocarcinoma cases / 2318502
Method involves applying endolymphatic- and autohemochemotherapy. Stage I of choriocarcinoma involves administering Methotrexate 20 mg/m2 as endolymphatic therapy at 1, 4, 8, 11, 15 and 18-th day; Rubomycin 30 mg/m2 at 1, 4, 8, 11, 15 and 18-th day Vinblastin - 15 mg/m2 at 1, 8 and 16-th day as autohemochemotherapy. Stage II of the disease involves administering Methotrexate 200 mg/m2 at the first day as endolymphatic therapy; Vincristin - 1.5 mg/m2 at 5,11, and 17-th day, Rubomycin 30 mg/m2 at 5, 8, 11, 14, 17 and 20-th day in a 21 days long course with 3 weeks long pause as autohemochemotherapy. The number of courses is 1-3. Stage III of the disease involves administering Methotrexate 200 mg/m2 as endolymphatic therapy, Etoposide -100 mg/m2, Kosmogen - 0.5 mg as autohemochemotherapy at the first day; Kosmogen - 0.5 mg as autohemochemotherapy at the second day; Vincristin - 1.0 mg/m2 Cyclophosphane 600 mg/m2, in 8 days long courses with 3-4 weeks interval and the number of courses is equal to 2-3.
 Method for complex therapy in patients with skin melanoma / 2318452
The present innovation deals with surgical therapy and chemoradiation therapy. Moreover, in pre-surgical period a patient's blood plasma should be incubated with the following chemopreparations: cisplatin 10 mg, methotrexate 25 mg, cyclophosphan 600 mg in a thermostat at 37°C for 30 min. Then it is important to inject the incubated plasma into a patient's subcutaneous fatty fiber due to paracentesis from 4 sides through the points marked under US control being beyond vascular system just under the focus of malignant growth. During the same day it is necessary to start gamma-therapy at the dosage of 2.4 Gy daily for 15 d, 2 d later one should carry out operation in the volume of wide dissection of the primary focus. The innovation enables to prolong the life period in patients, prevent tumor dissemination in the course of operation, decrease the risk for the development of disease relapses after surgical dissection of the primary tumor, creates the chance for direct supply of chemopreparations towards tumor focus and, also, develops conditions for their prolonged local impact.
Method of critical lower extremity ischemia treatment / 2357735
Invention concerns medicine, particularly vascular surgery, and can be applied in treatment of critical lower extremity ischemia. Method involves sampling of 400-500 ml of blood from vein. Blood is centrifuged for 15 minutes at 2000 rpm rate. Separated erythrocyte mass is dissolved by 200 ml of 0.9% physiological solution and returned to patient intravenously. 20 mcg of vasaprostan medication is added to 200 ml of plasma. Obtained mix is placed in thermostat and incubated for 20 minutes at 37°C, then injected to patient slowly by intravenous drop infusion for 2-3 hours once per day for 10 days.
|
FIELD: medicine. SUBSTANCE: invention concerns medicine, particularly orthopedics and extracorporal treatment methods, and can be applied in aseptic whirlbone necrosis and Perther disease treatment. Method involves venous blood sampling in amount of 300 ml with further blood separation into erythrocyte mass and plasma. Obtained erythrocyte mass is diluted by 200 ml of 0.9% physiological solution and administered intravenously to patient. 100 ml or patient's plasma is placed in thermostat and incubated for 20 minutes at 37°C. Further 20 mg of vasoprostan medicine is added to incubated plasma, and obtained mix is administered to patient by drop infusion for 1.5-2 hours once a day for 10 days. EFFECT: enhanced efficiency of the pathology treatment due to vasoprostan binding to plasma proteins and prolonged vasoprostan circulation in blood, resulting in arterial blood circulation improvement, venous stasis blocking in aseptic necrosis zone and significant acceleration of whirlbone acceleration. 2 tbl, 2 ex, 4 dwg
The invention relates to medicine, namely to orthopedics, and can be used in the treatment of avascular necrosis of the femoral head and of Perthes disease. Various methods of conservative treatment of aseptic necrosis of the femoral head and of Perthes disease including: standard pharmacotherapy aimed at improving microcirculation [1, 4], improving the tone of veins [4, 5], stimulation of regeneration [6]. In turn, all of the above methods have several disadvantages: 1) low efficiency of pharmacological preparations; 2) these funds only increase congestion of venous character in stage I and II disease; 3) a large percentage of disability. Closest to the present invention is a method of infusion of the use of antiplatelet agents (pentoxifylline, perturbat) in patients with Perthes disease [2, 3] However, this method also has several disadvantages: 1) the level of drug in the blood after intravenous injection, mainly depends on the speed of infusion and cardiac output; 2) selectively acts only on platelets without affecting other parts of hemostasis; 3) causes thrombocytopenia; 4) does not affect the muscles in the walls of blood vessels. The objective of the proposed method is to increase the effectiveness of treatment aseptic is about necrosis of the femoral head and of Perthes disease. The task reach due to the fact that the patient collect 300 ml of blood from a vein with subsequent separation of RBC mass and plasma obtained aricultural mass is diluted with 200 ml of 0.9% saline and returned to the patient intravenously and plasma in the amount of 100 ml are incubated in an incubator for 20 minutes at t°=37°C, followed by adding 20 mg of the drug "Vanaprastha", the resulting mixture was injected intravenously, drip in the interval of 1.5-2 hours once a day for 10 days. The method is as follows: 1) the patient carry out blood collection from a vein in the amount of 250-300 ml; 2) vials eksponirovannoi and heparinised blood centrifuged 15 minutes at a speed of 2000 rpm, after which the plasma exposium; 3) RBC mass is diluted with 0.9% saline solution in quantity (200 ml) and returned to the patient intravenously; 4) the plasma of the patient in the amount of 100 ml in Gamache put in a thermostat and incubated exposure 20 min at 37°C for activation of the protein in the blood plasma; 5) after incubation in the blood plasma is added 20 mg of the drug "Vazaprostan"; 6) the resulting mixture was injected intravenously to the patient within 1.5-2 hours, once a day for 10 days; 7) for 15 and 60 days and 90 days after treatment dopplered epicheskoe study in the medial circumflex artery and vein of the thigh. Comparison of treatment results was performed in 24 patients aged first and second childhood. The follow-up period was 15; 60; 90 day. To assess the effectiveness of the treatment was studied data dopplerography in the control group and study group. In the course of treatment established (table 1)that the proposed method can improve the speed parameters of arterial blood flow relative to the control group. By day 15 in the medial circumflex artery, the maximum flow velocity (Vmax) decreased by 5.8%, the minimum blood flow velocity (Vmin) increased 37.7%, eographically index (RI) decreased by 7.6% when increasing the diameter of the artery in 1,28 time. In the medial circumflex Vienna increased performance: Vmax increased by 25.6%, Vmin 19.4%, RI 29.1%, while the reduction of the diameter of the vein in 1.3 times, indicating a normalization of arterial and venous blood flow in the test group relative to the control. 60 days in the study group showed more pronounced reliable change indices, characterized by a moderate strengthening of the arterial and venous blood flow in age limits: in the artery Vmax decreased by 4.9%, Vmin increased by 8.2%, RI decreased by 2.1%, the artery diameter increased with 1.18. In venous blood flow: Vmax increased by 21.7%, Vmin 12.2%, RI by 13.7%, while the reduction of the diameter of the vein to 1.27 times relative to the control group. 90 the ducks in the artery Vmax decreased by 2.4%, Vmin increased by 15.1%, RI decreased by 6.7%, the artery diameter increased to 1.11 times. Also increased the performance of venous blood flow Vmax 16.5%, Vmin 7.2%, RI 13.3%, while the reduction of the diameter of the vein 1.13 times compared to the control group (table 1). In the control group, the recovery time of organ blood flow were long and were $ 98.4±4.7 days, while in the studied group of children the restoration of hemodynamics in GBq was already registered on the 15th day from the start of treatment (table 2). Thus the proposed method prolongs the clinical effect of the drug by binding with proteins (albumin) of plasma and more prolonged circulation in the blood. This leads to improved blood flow, blocking venous stasis in the area of avascular necrosis and contributes to a significant acceleration of the regeneration of the femoral head, which helped to reduce the duration of treatment in 2,8 times, greatly improve the efficiency of the treatment.
Clinical example 1. Patient Andrew K., age 11, he entered TOO GKB №20 15.01.06 diagnosed with Legg-Ka is live-Perthes disease (BP) to the left, Stage III (fragmentation). The child for 18.5 months complained of severe pains in the left hip joint (TBS)that occurred after exercise and walk. Was sent to the clinic for examination and decision of a question on operative treatment. On physical examination, a state of moderate severity, internal organs and clinical analyses without pathology. Locally were identified by restriction of external rotation of the right hip up to 20°, the limitation of internal rotation to 10°. Data dopplerography before treatment: medial circumflex artery Vmax (59,2 cm / sec), Vmin (11.1 cm / sec), RI (0,80%), d (1.4 mm), medial circumflex Vienna Vmax (15.9 cm / sec), Vmin (11.5 cm / sec), RI (0,23%), d (2,73 mm) The radiological examination confirmed the diagnosis of Perthes disease (BP) on the left, the stage of fragmentation (figure 1). X-ray examination found that the left hip joint (TBS) corresponded to group III clinical and radiographic changes. 15.01.06 the child had a surgical intervention (tuplesize of the femoral neck with subsequent osteoperforative neck and femoral head pin Ilizarov) on the left TBS. After surgery, the sick child, the course of in vitro pharmacotherapy. Patient collect 300 ml of blood from a vein with subsequent separation of RBC mass and plasma, the scientists aricultural mass is diluted with 200 ml of 0.9% saline and returned to the patient intravenously, and the plasma in the amount of 100 ml are incubated in an incubator for 20 minutes at t°=37°C, followed by adding 20 mg of the drug "Vanaprastha", the resulting mixture was injected intravenously, drip in the interval of 1.5-2 hours once a day for 10 days. Data dopplerography on 30.01.06, in the medial circumflex artery Vmax (55,2 cm / sec), Vmin (16,3 cm / sec), RI (0,70%), d (1,85 mm), medial circumflex veins Vmax (20.5 cm / sec), Vmin (14,4 cm / sec), RI (0,32%), d (2.1 mm). 30.01.06 on the radiograph positive dynamics of the recovery patterns of the femoral head. After the child received medical rehabilitation, performed the prescribed orthopedic mode. Through 4.8 months. after the first operation the radiological examination, he was diagnosed with stage V BP (Exodus) (figure 2). When ray study has shown a significant improvement in clinical and radiological condition TBS compared with the preoperative period. Thus, the use of extracorporeal infusion of vanaprastha in BP treatment was effective for the patient. During treatment was able to restore clinical and radiological condition of the affected TBS from III to I clinical-radiological group, to fully restore the anatomical parameters of the femoral head (HBR), which allowed to reduce the treatment time in 2.8 times. The wedge is ical example 2. Patient Dima W., age 7, entered TOO GKB №20 17.10.05 diagnosed with Legg-calve-Perthes disease right, stage III (fragmentation). The child within 27 months complained of fatigue, severe pains in the TBS that occurred after exercise and walk. Was sent CRH clinic for examination and decision of a question on conservative and surgical treatment. On physical examination, a state of moderate severity, internal organs and clinical analyses - without a pathology. Locally - was identified on the right positive symptom Trendelenburg and limitation of external rotation of the right hip up to 20°. Data dopplerography before treatment: medial circumflex artery Vmax (59,3 cm / sec), Vmin (11.2 cm / sec), RI (0,80%), d (1,41 mm), medial circumflex veins Vmax (15.8 cm / sec), Vmin (11.6 cm / sec), RI (0,24%), d (2,71 mm). The radiological examination confirmed the diagnosis of BP to the right, the stage of fragmentation (figure 3). The radiological examination established that the right-TBS corresponded to group III clinical and radiographic changes. 20.10.05 child day treatment (tuplesize of the femoral neck with subsequent osteoperforative neck and femoral head pin Ilizarov) and applying the standard conservative therapy with antiplatelet agents. Data dopplerography on 22.01.06, medial envelope artery the Vmax (55,7 cm / sec), Vmin (15.9 cm / sec), RI (0,73%), d (1,73 mm), medial circumflex Vienna Vmax (19.5 cm / sec), Vmin (13,9 cm / sec), RI (0,31%), d (2,49 mm). With 22.01.06 after registration on the radiograph positive dynamics of recovery patterns GBq, the child received medical rehabilitation, performed the prescribed orthopedic mode. Through 14.2 months. after the first surgery and conservative therapy for x-ray examination, he was diagnosed with stage V BP (Exodus) (figure 4). Chest x-ray is set to improve clinical and radiological condition TBS compared with the preoperative period. Right TBS corresponded II clinical-radiological group. Thus, the use of surgical treatment and the standard conservative therapy was not effective in the patient. During treatment was able to improve clinical and radiological condition of the affected TBS from III to II clinical-radiological group, however, full recovery of anatomical parameters GBq corresponding to group I, could not be reached. Compared with the prototype of the proposed method has the following advantages: resistant removing venous stasis in the proximal femur, normalization of arterial blood flow leading to improved revascularization of the affected epiphysis and a significant acceleration of regeneration of the femoral head, reducing the duration of treatment in 2.8 times. References 1. Bernstein S. Pathogenetic substantiation of methods of treatment, early detection and prevention of disease Legg-calve-Perthes disease in children: author. dis... Prof. the honey. Sciences. - Semipalatinsk, 1995. - 35 S. 2. Gafarov, HS Modern etiopathogenetic rationale for the treatment of Perthes disease / Hshape // Treatment of children and adolescents with orthopaedic diseases of the lower extremities. - Kazan, 1995. - S-220. 3. Kotelnikov G.P., S. p. Mironov, Miroshnichenko SCI Traumatology and Orthopaedics. U-M: GEOTAR-Media, 2006. - 400). 4. Studenikina, MA Osteochondropathy // Manual of pediatric arthrology / Mastodynia, Blu - L., 1987. - S.226-236. 5. Schulitz K.R., Dustmann ACTING Morbus Perthes. - Berlin: Springer, 1991. - 402 s. 6. Krauspe R., Raab P Morbus Perthes // Orthopaede. - 1997. - 26, 3. - S.289-302. A method for the treatment of avascular necrosis of the femoral head and of Perthes disease, including intravenous antiplatelet agents under the control of Doppler, characterized in that the patient collect 300 ml of blood from a vein with subsequent separation of RBC mass and plasma obtained aricultural mass is diluted with 200 ml of 0.9%saline and returned to the patient intravenously and plasma in the amount of 100 ml are incubated in an incubator for 20 minutes at t-37°C is followed by adding 20 mg of the drug "Vazaprostan", the resulting mixture was injected intravenously, drip in the interval of 1.5-2 hours once a day for 10 days.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||